Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Asher Bio Announces Clinical Trial Collaboration And Supply Agreement With Amgen On Etakafusp Alfa In Combination With Bispecific T-cell Engager In Patients With Small Cell Lung Cancer
Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a clinical trial collaboration and supply agreement with Amgen (NASDAQ:AMGN) to evaluate etakafusp alfa (formerly known as AB248), Asher Bio's investigational CD8+ T cell targeted interleukin-2 (IL-2) immunotherapy, in combination with IMDELLTRA (tarlatamab), Amgen's DLL3-targeting Bispecific T-cell Engager (BiTE) therapy, in patients with extensive-stage small cell lung cancer (ES-SCLC).
Asher Biotherapeutics是一家生物技術公司，專注於開發針對癌症和傳染病的精確靶向免疫療法。今天，該公司宣佈與安進（納斯達克：AMGN）達成臨牀試驗合作和供給協議，以評估其實驗性CD8+ T細胞靶向白介素-2（IL-2）免疫療法etakafusp ALFA（以前稱爲AB248）與安進的DLL3靶向雙特異性T細胞連接器（BiTE）療法IMDELLTRA（tarlatamab）聯合應用於廣泛期小細胞肺癌（ES-SCLC）患者的效果。
